^van Es MA, Veldink JH, Saris CG, Blauw HM, van Vught PW, Birve A, et al. (October 2009). "Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis". Nature Genetics. 41 (10): 1083–1087. doi:10.1038/ng.442. PMID19734901. S2CID8659710.
^Bosco DA, Landers JE (December 2010). "Genetic determinants of amyotrophic lateral sclerosis as therapeutic targets". CNS & Neurological Disorders Drug Targets. 9 (6): 779–790. doi:10.2174/187152710793237494. PMID20942785.
^Su XW, Broach JR, Connor JR, Gerhard GS, Simmons Z (June 2014). "Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research". Muscle & Nerve. 49 (6): 786–803. doi:10.1002/mus.24198. PMID24488689. S2CID38375893.
^Hartlage-Rübsamen M, Waniek A, Roßner S (February 2013). "Munc13 genotype regulates secretory amyloid precursor protein processing via postsynaptic glutamate receptors". International Journal of Developmental Neuroscience. 31 (1): 36–45. doi:10.1016/j.ijdevneu.2012.10.001. PMID23070049. S2CID28216850.